ID

39894

Beschreibung

Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01741116

Link

https://clinicaltrials.gov/show/NCT01741116

Stichworte

Versionen (1)
  1. 01.03.20 01.03.20 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

1. März 2020

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Hormone Refractory Prostate Cancer NCT01741116

Englisch

Eligibility Hormone Refractory Prostate Cancer NCT01741116

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with histologically confirmed progressive metastatic androgen-independent adenocarcinoma of the prostate with radiographic evidence of disease.
Beschreibung

Adenocarcinoma of the prostate metastatic Progressive Androgen-independent | Disease Radiography

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0862636
UMLS CUI [1,2]
C0205329
UMLS CUI [1,3]
C2986466
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C0043299
no more than two previous cytotoxic chemotherapy
Beschreibung

Cytotoxic Chemotherapy Quantity

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0677881
UMLS CUI [1,2]
C1265611
castration level of testosterone (< 50 ng/dl) achieved by orchiectomy or gonadotropin-releasing hormone(gnrh) agonist
Beschreibung

Castration Levels of Testosterone | Orchiectomy | Gonadotropin Releasing Hormone Agonist

Datentyp

boolean

Alias
UMLS CUI [1]
C4289828
UMLS CUI [2]
C0029189
UMLS CUI [3]
C2267073
eastern cooperative oncology group(ecog) performance status 0 - 2
Beschreibung

ECOG performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
finished any study drug or chemotherapy earlier than 4 weeks before the first administration of the study drug.
Beschreibung

Investigational New Drugs Treatment completed | Chemotherapy Completed

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C0580352
UMLS CUI [2,1]
C0392920
UMLS CUI [2,2]
C0205197
age ≥ 20 years old
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
patients must have the following laboratory values:
Beschreibung

Laboratory Results Required

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1254595
UMLS CUI [1,2]
C1514873
absolute neutrophil count (anc) ≥ 1.5 x 109/l
Beschreibung

Absolute neutrophil count

Datentyp

boolean

Alias
UMLS CUI [1]
C0948762
platelets ≥ 75 x 109/l
Beschreibung

Platelet Count measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C0032181
hemoglobin (hgb) > 8 g/dl
Beschreibung

Hemoglobin measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C0518015
serum total bilirubin: ≤ 1.5 x uln
Beschreibung

Serum total bilirubin measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C1278039
alanine transaminase(alt) and aspartate aminotransferase(ast) ≤ 2.0 x upper limit of normal(uln) with or without liver metastases
Beschreibung

Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Secondary malignant neoplasm of liver | Secondary malignant neoplasm of liver Absent

Datentyp

boolean

Alias
UMLS CUI [1]
C0201836
UMLS CUI [2]
C0201899
UMLS CUI [3]
C0494165
UMLS CUI [4,1]
C0494165
UMLS CUI [4,2]
C0332197
serum creatinine ≤ 1.5 x uln or serum creatinine >1.5 - 3 x uln or 1.5 x uln<serum creatinine < 3 x uln, if calculated creatinine clearance (crcl) is ≥
Beschreibung

Creatinine measurement, serum

Datentyp

boolean

Alias
UMLS CUI [1]
C0201976
30 ml/min using the cockcroft-gault equation, see formula below:
Beschreibung

Estimation of creatinine clearance by Cockcroft-Gault formula

Datentyp

boolean

Alias
UMLS CUI [1]
C2711451
crcl = [140-age (years)] x weight (kg) / [72 x serum cr (mg/dl)] (if patient is female multiply the above by 0.85)
Beschreibung

Estimation of creatinine clearance by Cockcroft-Gault formula | Gender

Datentyp

boolean

Alias
UMLS CUI [1]
C2711451
UMLS CUI [2]
C0079399
patients who give a written informed consent obtained according to local guidelines
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients eligible for this study must not meet any of the following criteria
Beschreibung

Exclusion Criteria Any

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1552551
patients with known brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases
Beschreibung

Metastatic malignant neoplasm to brain | Sign or Symptom Metastatic malignant neoplasm to brain | Radiologic Imaging Procedure Absent

Datentyp

boolean

Alias
UMLS CUI [1]
C0220650
UMLS CUI [2,1]
C3540840
UMLS CUI [2,2]
C0220650
UMLS CUI [3,1]
C3897780
UMLS CUI [3,2]
C0332197
patients with another primary malignancy within 3 years prior to starting study drug, with the exception of adequately treated in-situ carcinoma of the uterine cervix, basal or squamous cell carcinoma or non-melanomatous skin cancer
Beschreibung

Cancer Other | Exception Carcinoma in situ of uterine cervix Treated | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma Treated | Exception Skin carcinoma Treated

Datentyp

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0851140
UMLS CUI [2,3]
C1522326
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0007117
UMLS CUI [3,3]
C1522326
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0007137
UMLS CUI [4,3]
C1522326
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0699893
UMLS CUI [5,3]
C1522326
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Hormone Refractory Prostate Cancer NCT01741116

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Adenocarcinoma of the prostate metastatic Progressive Androgen-independent | Disease Radiography
Item
patients with histologically confirmed progressive metastatic androgen-independent adenocarcinoma of the prostate with radiographic evidence of disease.
boolean
C0862636 (UMLS CUI [1,1])
C0205329 (UMLS CUI [1,2])
C2986466 (UMLS CUI [1,3])
C0012634 (UMLS CUI [2,1])
C0043299 (UMLS CUI [2,2])
Cytotoxic Chemotherapy Quantity
Item
no more than two previous cytotoxic chemotherapy
boolean
C0677881 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Castration Levels of Testosterone | Orchiectomy | Gonadotropin Releasing Hormone Agonist
Item
castration level of testosterone (< 50 ng/dl) achieved by orchiectomy or gonadotropin-releasing hormone(gnrh) agonist
boolean
C4289828 (UMLS CUI [1])
C0029189 (UMLS CUI [2])
C2267073 (UMLS CUI [3])
ECOG performance status
Item
eastern cooperative oncology group(ecog) performance status 0 - 2
boolean
C1520224 (UMLS CUI [1])
Investigational New Drugs Treatment completed | Chemotherapy Completed
Item
finished any study drug or chemotherapy earlier than 4 weeks before the first administration of the study drug.
boolean
C0013230 (UMLS CUI [1,1])
C0580352 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
Age
Item
age ≥ 20 years old
boolean
C0001779 (UMLS CUI [1])
Laboratory Results Required
Item
patients must have the following laboratory values:
boolean
C1254595 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
Absolute neutrophil count
Item
absolute neutrophil count (anc) ≥ 1.5 x 109/l
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement
Item
platelets ≥ 75 x 109/l
boolean
C0032181 (UMLS CUI [1])
Hemoglobin measurement
Item
hemoglobin (hgb) > 8 g/dl
boolean
C0518015 (UMLS CUI [1])
Serum total bilirubin measurement
Item
serum total bilirubin: ≤ 1.5 x uln
boolean
C1278039 (UMLS CUI [1])
Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Secondary malignant neoplasm of liver | Secondary malignant neoplasm of liver Absent
Item
alanine transaminase(alt) and aspartate aminotransferase(ast) ≤ 2.0 x upper limit of normal(uln) with or without liver metastases
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0494165 (UMLS CUI [3])
C0494165 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
Creatinine measurement, serum
Item
serum creatinine ≤ 1.5 x uln or serum creatinine >1.5 - 3 x uln or 1.5 x uln<serum creatinine < 3 x uln, if calculated creatinine clearance (crcl) is ≥
boolean
C0201976 (UMLS CUI [1])
Estimation of creatinine clearance by Cockcroft-Gault formula
Item
30 ml/min using the cockcroft-gault equation, see formula below:
boolean
C2711451 (UMLS CUI [1])
Estimation of creatinine clearance by Cockcroft-Gault formula | Gender
Item
crcl = [140-age (years)] x weight (kg) / [72 x serum cr (mg/dl)] (if patient is female multiply the above by 0.85)
boolean
C2711451 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
Informed Consent
Item
patients who give a written informed consent obtained according to local guidelines
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Exclusion Criteria Any
Item
patients eligible for this study must not meet any of the following criteria
boolean
C0680251 (UMLS CUI [1,1])
C1552551 (UMLS CUI [1,2])
Metastatic malignant neoplasm to brain | Sign or Symptom Metastatic malignant neoplasm to brain | Radiologic Imaging Procedure Absent
Item
patients with known brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases
boolean
C0220650 (UMLS CUI [1])
C3540840 (UMLS CUI [2,1])
C0220650 (UMLS CUI [2,2])
C3897780 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
Cancer Other | Exception Carcinoma in situ of uterine cervix Treated | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma Treated | Exception Skin carcinoma Treated
Item
patients with another primary malignancy within 3 years prior to starting study drug, with the exception of adequately treated in-situ carcinoma of the uterine cervix, basal or squamous cell carcinoma or non-melanomatous skin cancer
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0851140 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0007137 (UMLS CUI [4,2])
C1522326 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0699893 (UMLS CUI [5,2])
C1522326 (UMLS CUI [5,3])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video